Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 1.28
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
NextCell Pharma AB, a biopharmaceutical company, engages in the research and development of novel stem cell therapies in Sweden. The company develops ProTrans, a drug candidate comprising stem cells primarily for treating autoimmune and inflammatory diseases. It also provides Cellaviva, a stem cell bank for the family-saving of stem cells from umbilical cord blood and...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell